ImmunoScape, Cue Biopharma In Deal To Develop Next-Gen Cancer Immunotherapies
Kuala lumpur: ImmunoScape Pte Ltd, a Singapore-based biotech spin-out backed by Amgen Ventures and EDBi, has signed an exclusive in-licensing agreement with Cue Biopharma Inc to develop a new class of T cell receptor (TCR)-based immunotherapies target…